Cellebrite DI (NASDAQ:CLBT) Hits New 52-Week High – Time to Buy?

Cellebrite DI Ltd. (NASDAQ:CLBTGet Free Report) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $24.32 and last traded at $24.19, with a volume of 1046492 shares traded. The stock had previously closed at $23.00.

Analysts Set New Price Targets

A number of research analysts have weighed in on CLBT shares. Craig Hallum raised their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Needham & Company LLC upped their price objective on shares of Cellebrite DI from $21.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. increased their price objective on Cellebrite DI from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Monday, December 16th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $21.57.

Get Our Latest Analysis on Cellebrite DI

Cellebrite DI Trading Up 0.2 %

The company’s fifty day simple moving average is $21.61 and its 200 day simple moving average is $18.25. The stock has a market capitalization of $4.94 billion, a P/E ratio of -15.48, a P/E/G ratio of 3.52 and a beta of 1.46.

Cellebrite DI (NASDAQ:CLBTGet Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.05. The company had revenue of $106.90 million during the quarter, compared to analyst estimates of $102.06 million. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The firm’s quarterly revenue was up 27.0% on a year-over-year basis. During the same quarter last year, the company earned $0.09 earnings per share. Equities research analysts predict that Cellebrite DI Ltd. will post 0.32 earnings per share for the current year.

Institutional Investors Weigh In On Cellebrite DI

Institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC increased its holdings in shares of Cellebrite DI by 136.3% in the 3rd quarter. FMR LLC now owns 5,616,757 shares of the company’s stock worth $94,586,000 after buying an additional 3,239,307 shares during the last quarter. Meitav Investment House Ltd. increased its stake in Cellebrite DI by 29.7% in the third quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company’s stock valued at $34,797,000 after acquiring an additional 473,293 shares during the last quarter. Pembroke Management LTD increased its stake in Cellebrite DI by 24.3% in the third quarter. Pembroke Management LTD now owns 1,908,345 shares of the company’s stock valued at $32,137,000 after acquiring an additional 372,619 shares during the last quarter. Principal Financial Group Inc. purchased a new stake in Cellebrite DI during the third quarter valued at about $23,402,000. Finally, Two Sigma Advisers LP lifted its stake in Cellebrite DI by 9.8% during the third quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company’s stock worth $22,584,000 after purchasing an additional 120,000 shares during the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

About Cellebrite DI

(Get Free Report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Read More

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.